Dr Reddys Laboratories Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Dr Reddys Laboratories Ltd is ₹ 1322 as of 30 Apr 15:30 . The P/E Ratio of Dr Reddys Laboratories Ltd changed from 38.5 on March 2021 to 16.9 on March 2025 . This represents a CAGR of -15.18% over 5 yearsThe P/E Ratio of Sun Pharmaceutical Industries Ltd changed from 49.4 on March 2021 to 38.1 on March 2025 . This represents a CAGR of -5.06% over 5 years The Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 75095 crore on March 2021 to ₹ 95465 crore on March 2025 . This represents a CAGR of 4.92% over 5 yearsThe Market Cap of Sun Pharmaceutical Industries Ltd changed from ₹ 143384 crore on March 2021 to ₹ 416392 crore on March 2025 . This represents a CAGR of 23.77% over 5 years The revenue of Dr Reddys Laboratories Ltd for the Dec '25 is ₹ 9024 crore as compare to the Sep '25 revenue of ₹ 9158 crore. This represent the decline of -1.46% The revenue of Sun Pharmaceutical Industries Ltd for the Dec '25 is ₹ 16099 crore as compare to the Sep '25 revenue of ₹ 14948 crore. This represent the growth of 7.7% The ebitda of Dr Reddys Laboratories Ltd for the Dec '25 is ₹ 2158 crore as compare to the Sep '25 ebitda of ₹ 2340 crore. This represent the decline of -7.76% The ebitda of Sun Pharmaceutical Industries Ltd for the Dec '25 is ₹ 5037 crore as compare to the Sep '25 ebitda of ₹ 4996 crore. This represent the growth of 0.82% The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1392 crore to ₹ 1189 crore over 7 quarters. This represents a CAGR of -8.60% The net profit of Sun Pharmaceutical Industries Ltd changed from ₹ 2871 crore to ₹ 3401 crore over 7 quarters. This represents a CAGR of 10.16% The Dividend Payout of Dr Reddys Laboratories Ltd changed from 19.03 % on March 2021 to 12.47 % on March 2025 . This represents a CAGR of -8.11% over 5 yearsThe Dividend Payout of Sun Pharmaceutical Industries Ltd changed from 213.61 % on March 2021 to 89.64 % on March 2025 . This represents a CAGR of -15.94% over 5 years .

About Dr Reddys Laboratories Ltd

Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's portfolio of products and services include Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Dr. Reddy's operates in markets across the globe.
Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

About Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.
It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates.
The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids.

FAQs for the comparison of Dr Reddys Laboratories Ltd and Sun Pharmaceutical Industries Ltd

Which company has a larger market capitalization, Dr Reddys Laboratories Ltd or Sun Pharmaceutical Industries Ltd?

Market cap of Dr Reddys Laboratories Ltd is 110,420 Cr while Market cap of Sun Pharmaceutical Industries Ltd is 433,847 Cr

What are the key factors driving the stock performance of Dr Reddys Laboratories Ltd and Sun Pharmaceutical Industries Ltd?

The stock performance of Dr Reddys Laboratories Ltd and Sun Pharmaceutical Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dr Reddys Laboratories Ltd and Sun Pharmaceutical Industries Ltd?

As of May 3, 2026, the Dr Reddys Laboratories Ltd stock price is INR ₹1322.95. On the other hand, Sun Pharmaceutical Industries Ltd stock price is INR ₹1808.2.

How do dividend payouts of Dr Reddys Laboratories Ltd and Sun Pharmaceutical Industries Ltd compare?

To compare the dividend payouts of Dr Reddys Laboratories Ltd and Sun Pharmaceutical Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.